Superselective intraarterial cerebral infusion of bevacizumab: a revival of interventional neuro-oncology for malignant glioma.

摘要: Glioblastoma Multiforme (GBM) is a uniformly fatal disease with median survival of approximately 15 months. Recent monoclonal antibody therapies such as Bevacizumab (Avastin) have been shown to be active in GBM and prolong patients recurrent malignant glioma. Therefore, routinely receive intravenous (i.v.) (10 mg/kg) every two weeks when they recurred following standard therapy chemoradiation. I.v Bevacizumab; however, can cause significant systemic side effects including bowel perforation pulmonary embolism. In addition, the blood brain barrier (BBB) continues provide an obstacle effective delivery tumor bed. order overcome BBB, limit toxicity i.v. Bevacizumab, we begun Phase I clinical trial test safety transient disruption intraarterial (IA) Mannitol followed by superselective cerebral infusion (SIACI) Bevacizumab. This case report describes technical aspects this procedure its associated benefits risks. novel method, which may herald revival Interventional Neuro-oncology, significantly alter way administered GBM.